Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord blood mononuclear cell infusion for acute cervical spinal cord injury
ChiCTR2400085285Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3 trial of umbilical cord blood mononuclear cells in spinal cord injury (SCI) and cervical spinal cord injury (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: American Spinal Injury Association impairment scale. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
umbilical cord blood mononuclear cells
03
Conditions
spinal cord injury (SCI)cervical spinal cord injury
Beyond the preview
Go deeper on ChiCTR2400085285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085285.